Search Results



Your search for Lawrence N. Shulman, MD matches 17 pages

Showing 1 - 17


issues in oncology

Evolving Standards and Quality Metrics Ensure High-Quality Cancer Programs

Dr. Shulman is Deputy Director, Clinical Services, and Director of the Center for Global Cancer Medicine, Abramson Cancer Center; and Professor of Medicine, Hospital of the University of Pennsylvania, Philadelphia. IN 2008, WHEN ALLEN LICHTER, MD, FASCO, then Chief Executive Officer of ASCO,...

ASCO Honors Leaders in Cancer Care With 2018 Special Awards

ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked to transform...

survivorship

Lawrence N. Shulman, MD, on The New Survivorship Standard: Expert Perspective

Lawrence N. Shulman, MD, of Abramson Cancer Center at the University of Pennsylvania, discusses the Commission on Cancer’s efforts to promote robust survivorship care and how its new recommendations will affect clinical practice and patients.

issues in oncology

Survival as Quality Metric in Cancer Care

In a National Cancer Data Base study reported in the Journal of Oncology Practice, Shulman et al found little difference in risk-adjusted cancer mortality rates among individual hospitals, suggesting survival may not be an ideal quality metric at the individual hospital level. However, survival was ...

Lawrence N. Shulman, MD, FACP, Named Chair of American College of Surgeons’ Commission on Cancer

Lawrence N. Shulman, MD, FACP, Professor of Medicine in the Perelman School of Medicine and Deputy Director for Clinical Services of the Abramson Cancer Center at the University of Pennsylvania, has been named the new Chair of the Commission on Cancer of the American College of Surgeons. The...

global cancer care

Lawrence N. Shulman, MD, and Daniel A. Goldstein, MD: Expert Perspectives on Issues in Global Cancer Care

Lawrence N. Shulman, MD, of Abramson Cancer Center at the University of Pennsylvania, and Daniel A. Goldstein, MD, of the Rabin Medical Center, discuss global challenges in cancer care, including treating patients in areas lacking resources, and cancer drug price disparities (Abstract LBA6500).

survivorship

Lawrence N. Shulman, MD, on Survival as a Measure of Quality and Advances in Therapy

Lawrence N. Shulman, MD, of the University of Pennsylvania, discusses his paper, which explores lessons learned from analyses of the National Cancer Data Base. (Abstract 173)

global cancer care
health-care policy

Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss the delivery of cancer care in resource-constrained settings such as Rwanda and Haiti, and plans to conduct research in basic tumor biology of patients in these...

issues in oncology

Cancer Informatics: A Future Necessity, but Challenges Abound

The National Cancer Policy Forum of the Institute of Medicine (IOM) recently convened a workshop on cancer informatics to examine and discuss needs and challenges facing biomedical researchers, which will in turn affect the way oncology is practiced in the future. “This is a time of huge scientific ...

Dana-Farber Researcher’s Work with Partners in Health Brings Quality Cancer Care to Rwanda

Lawrence N. Shulman, MD, Chief Medical Officer at Dana-Farber Cancer Institute, grew up in New York City. A product of the public school system, Dr. Shulman entered Syracuse University as a history major, only to realize that studying the past, although important, wasn’t for him. “I wanted a field...

Special Anniversary Issue: Narratives in Oncology

The ASCO Post is pleased to present this special anniversary edition in recognition of the publication's 3rd year serving the oncology community. We hope you enjoy this special commemorative issue profiling several of the many leaders in the oncology community. In coming issues ofThe ASCO Postand...

global cancer care
health-care policy

Cancer Care in Rwanda: A Model of Creative Partnerships

While disparities in cancer care remain problematic in wealthy industrial nations like the United States, the challenges faced in poorer regions of the world are, by comparison, inestimable. Nationally regarded health-care expert Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, is part of...

breast cancer
issues in oncology

Breast Cancer Care in the Era of Accountable Care Organizations

Prepare for big changes ahead, Lawrence N. Shulman, MD, Senior Vice President for Medical Affairs at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School in Boston, told oncologists at the 2013 Breast Cancer Symposium.1 One change is the emergence of...

issues in oncology
global cancer care
health-care policy

Delivering Cancer Care in Low-Income Countries

In eealthy industrialized nations like the United States, escalating costs of cancer care have put the term “cost-effective care” on the forefront of health-care policy discussions. However, the cost issues we wrestle with in our $3 trillion health-care system are vague abstractions for much of the ...

issues in oncology

A National Cancer Database and Cancer Care Quality Improvement

At this year’s Quality Care Symposium, Lawrence N. Shulman, MD, Chief of Staff and Director of the Center for Global Cancer Medicine at Dana-Farber Cancer Institute, Boston, looked at the issue of quality infrastructure development through the prism of several tools developed by the American...

issues in oncology

Journal of Clinical Oncology Special Series Issues Provide Updates on Important Topics in Oncology Practice

Journal of Clinical Oncology (JCO) annually publishes several Special Series of reviews—disease-specific issues dedicated to providing readers with concise, authoritative updates on important topics in oncology practice. Each issue of the Special Series explores one specific area of cancer care...

breast cancer

Adjuvant Paclitaxel Not Equivalent to Doxorubicin/Cyclophosphamide in Breast Cancer With 0 to 3 Positive Axillary Nodes

In the phase III Cancer and Leukemia Group B (CALGB) 40101/Alliance trial reported in the Journal of Clinical Oncology, Shulman et al found that noninferiority of adjuvant single-agent paclitaxel was not established vs doxorubicin/cyclophosphamide for relapse-free survival in women with operable...

Advertisement

Advertisement


Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.